Get started
Author

Alexander S. Pristupa

Observed names: A S Pristupa, A. Pristupa, A. S. Pristupa, Alexander Pristupa, Alexander S Pristupa, Alexandr S. Pristupa, Pristupa, Alexander, Приступа Александр Сергеевич
ORCID: 0000-0001-6842-5660
Observed ORCID: 0000-0001-6842-5660
OpenAlex ID: A5032515801
Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis
2018 · John Mascarenhas, Ronald Hoffman, et al. · JAMA Oncology · 400
PDF
Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial
2017 · Andrew D Zelenetz, Jacqueline C Barrientos, et al. · The Lancet Oncology · 250
PDF
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
2018 · G. Fraser, P. Cramer, et al. · Leukemia · 118
PDF
Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/µl
2016 · John Mascarenhas, Ronald Hoffman, et al. · Blood · 37
Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
2015 · Asher Alban Akmal Chanan-Khan, Paula Cramer, et al. · Journal of Clinical Oncology · 18
Use of CYP3Ai and impact on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine in the VIALE‐A study
2022 · Brian A. Jonas, Courtney DiNardo, et al. · American Journal of Hematology · 15
PDF
Idelalisib addition has neutral to beneficial effects on quality of life in bendamustine/rituximab-treated patients: results of a phase 3, randomized, controlled trial
2019 · Marco Montillo, Árpád Illés, et al. · Health and Quality of Life Outcomes · 12
PDF
Interim results of the Ph-negative acute lymphoblastic leukemia treatment in adult patients (results of Russian research group of ALL treatment (RALL))
2015 · E. N. Parovichnikova, V. V. Troitskaya, et al. · DOAJ (DOAJ: Directory of Open Access Journals) · 9
CYP3A inhibitors and impact of these agents on outcomes in patients with acute myeloid leukemia treated with venetoclax plus azacitidine on the VIALE-A study
2020 · Brian A Jonas, Courtney D. Dinardo, et al. · Blood · 4
Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.
2015 · Asher Alban Akmal Chanan-Khan, Paula Cramer, et al. · Journal of Clinical Oncology · 4
A phase 3, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).
2014 · Herbert Aaron Eradat, Tadeusz Robak, et al. · Journal of Clinical Oncology · 4
Early Changes in Circulating T-Cell Immune Profiles in Patients with Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Data from the Phase 3, Double-Blind HELIOS Trial
2016 · Rajendra Damle, Michael Schaffer, et al. · Blood · 3
Non-Intensive but Constant and Exhausting Action on the Leukemic Clone Is a Reasonable and Effective Treatment Approach in Adult Acute Lymphoblastic Leukemia: Results of the Russian Acute Lymphoblastic Leukemia (RALL) Study Group
2014 · Elena N. Parovichnikova, Vera Troitskaya, et al. · Blood · 3
Analysis of Recorded Morbidity, Prevalence and Hospital Mortality of Patients with Symptomatic Multiple Myeloma in the Ryazan Region for 10 Years
2022 · Sergey G. Bolotin, Mariya S. Zenina, et al. · I P Pavlov Russian Medical Biological Herald · 2
Ibrutinib Increases the Systemic Exposure of Rituximab: Pharmacokinetic Results From the Helios Trial
2017 · P. Cramer, F. Demirkan, et al. · Hematological Oncology · 1
PDF
Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial
2016 · Paula Cramer, Fatih Demirkan, et al. · Blood · 1
Absence of High-Dose Consolidation Courses and Low Numbers of Allogeneic HSCTs Did Not Affect Overall Optimistic Results in B-Cell Precursor Ph-Negative Adult ALL Patients Treated By Non-Intensive but Non-Interruptive ALL-2009 Protocol: Data of the Russian ALL Study Group
2015 · Elena N. Parovichnikova, Vera V. Troitskaya, et al. · Blood · 1
Risk factors associated with mortality in patients with multiple myeloma
2025 · S. G. Bolotin, A. V. Solovieva, et al. · Meditsinskiy sovet = Medical Council
PDF
Генетические аспекты диабетической нефропатии у больных сахарным диабетом 2-го типа
2017 · Берстнева Светлана Вячеславовна, Дубинина Инесса Ивановна, et al. · Medical Almanac
Ibrutinib vs Clorambucilo-Burger-2015-e-pub
2016 · Burger Ja, Alessandra Tedeschi, et al.
European Union (EU) vs. non-EU (NOEU) countries study compliance: the experience of the phase III FLORENCE study testing febuxostat in the Tumor Lysis Syndrome (TLS) prevention.
2015 · Simone Baldini, Cristina Rossi, et al. · Journal of Clinical Oncology
Decision Driven Factors for Allopurinol Dosage in Tumor Lysis Syndrome Prophylaxis: The European Experience of the Florence Pivotal Study
2014 · Simone Baldini, Cristina Rossi, et al. · Blood
Conventional 7+3 Consolidation Is Equal in Long-Term Outcome to High Dose ARA-C in Case of the High Total Doses of Different Anthracyclines/Anthracenedione in Induction/Consolidation - the Interim Results of Russian Randomized Multicenter AML-10 Trial
2014 · Valeri G Savchenko, Elena N. Parovichnikova, et al. · Blood
A randomized double-blind phase III pivotal study of febuxostat (FEB) versus allopurinol (ALL) in the prevention of tumor lysis syndrome (TLS): Florence study.
2014 · Michele Spina, Zsolt Nagy, et al. · Journal of Clinical Oncology
Эффективность Лечения Взрослых Больных Острым Т-лимфобластным Лейкозом По Протоколу Олл-2009 Российской Научно-исследовательской Группы По Изучению Острых Лейкозов
2013 · E N Parovichnikova, C A Klyasova, et al. · CyberLeninK (CyberLeninka)
Works count: 29
Citation count: 882
H-index: 8
I10-index: 7
Year
Topic
Type